GleamWall
中文EN

GIPL Global Innovative Platforms Inc.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1837774 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-20.9%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-361.7%
Net margin-361.7%
FCF margin—
EBITDA margin—

Returns

ROE-190.0%
ROA-180.9%
ROIC (approx.)-395.6%
Asset turnover0.50x

Leverage & solvency

Liabilities / assets1.4%
Debt / equity0.00x
Current ratio34.73x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-91.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-06-302026Q22026-03-312026Q12025-12-312025Q4*2025-09-302025Q32025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$50,700$106,500$30,000$0$0$0—$0
R&D expense$3,380$1,825$10,681$362,099$8,962$3,541$34,250—
SG&A expense——$68,748-$148,216$211,818$151,351$86,217$76,482
Operating income-$241,611-$151,386-$49,429-$234,616-$211,818-$151,351-$120,467-$76,482
Pretax income-$241,611-$151,386-$49,429-$234,616-$211,818-$151,351-$120,467-$76,482
Income tax$0$0——$0$0—$0
Net income-$241,611-$151,386-$49,429-$234,616-$211,818-$151,351-$120,467-$76,482
EBITDA-$229,759-$138,225-$44,416—-$211,818———
EPS (basic)-0.01-0.00-0.00—-0.01-0.00-0.00—
EPS (diluted)——-0.00—-0.01-0.00-0.00—
Weighted avg. shares (diluted)0044.54M—0035.75M—
Balance sheet
Cash & equivalents$244,235$327,270$49,004$17,828$198,137$155,909$148,459$15
Receivables$14,700$18,000—$0————
Current assets$270,609$366,570$54,516$199,275$209,160$166,932$148,459$15
PP&E, net$264,870$221,606$170,435$0$0$0$0$0
Intangibles$3,782$3,782—$0————
Total assets$539,261$591,958$224,951$199,275$209,160$166,932$148,459$15
Current liabilities$7,791$2,284$65,784$11,609$27,823$3,229$14,407$33,153
Short-term debt$5,616$0—$1,500————
Total liabilities$7,791$2,284$65,784$11,609$27,823$3,229$14,407$33,153
Shareholders' equity$531,470$589,674$159,567$187,666$181,337$163,703$134,051-$33,138
Shares outstanding49.75M48.68M45.98M44.48M42.18M39.11M37.30M33.75M
Cash flow statement
Operating cash flow-$133,565-$149,473$12,676-$64,861-$184,273-$173,549-$138,057-$59,713
Capital expenditure$55,116———$0———
Free cash flow-$188,681———-$184,273———
Investing cash flow-$55,116——-$175,448$0——$0
Financing cash flow$105,646$495,854$18,500$60,000$226,501$180,999$286,501$49,582
Depreciation & amortization$11,852$13,161$5,013—$0———

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.